Update zur Pathophysiologie des Restless-Legs-Syndroms

Zusammenfassung

Die Ursachen des Restless-Legs-Syndroms (RLS) sind heterogen. Die sogenannten idiopathischen RLS-Syndrome, die vor allem bei jüngeren Patienten unter 30 Jahren symptomatisch werden, sind häufig familiär bedingt. Die ersten Gene wurden in diesem Jahr im Gen MEIS1, im BTBD9 Gen und in den Genen, die die mitogenaktivierende Proteinkinase MAP2K5 und den Transkriptionsfaktor LBXCOR1 codieren, jeweils auf den Chromosomen 2p, 6p und 15q, identifiziert. Eine Vielzahl symptomatischer Ursachen wie Eisenmangel, Urämie, Polyneuropathie und andere verursachen die sog. sekundären Formen. Von besonderem pathophysiologischem Interesse ist derzeit die Klärung der Frage, warum die dopaminerge Therapie für idiopathische wie symptomatische Formen so effizient ist und das hiermit verbundene Problem der sogenannten Augmentation. Unter Augmentation versteht man eine therapieinduzierte paradoxe Verstärkung der Symptome des RLS durch dopaminerge Therapie, wahrscheinlich dosisabhängig. Sie tritt bei bis zu 60 % der Patienten vorzugsweise unter L-Dopa aber auch unter der Therapie mit Dopaminagonisten auf. Augmentation wird wahrscheinlich durch Verschiebung des Gleichgewichtes zugunsten erregender dopaminerger D1-Rezeptoren und zuungunsten hemmender D2-Rezeptoren wahrscheinlich spinal verursacht. Eisenmangel stellt einen auslösenden oder verstärkenden Faktor dar. Die Therapie mit L-Dopa oder Dopaminagonisten sollte daher wesentlich niedriger als beim Parkinsonsyndrom gehalten werden. Eisensubstitution und Opiate sind die Mittel der Wahl, um das Risiko der Augmentation zu minimieren und ggfs. zu therapieren.

Abstract

The Restless Legs Syndrome (RLS) is a heterogeneous disease. The so-called idiopathic RLS syndromes affect preferentially younger patients before the age of 30 and are with a higher likelihood familial. This year intronic variants in the homeobox gene MEIS1, the BTBD9 gene encoding a BTB(POZ) domain as well as variants in a third locus containing the genes encoding mitogen-activated protein kinase MAP2K5 and the transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, were identified. Symptomatic or secondary forms encompass iron deficiency, uremia, polyneuropathy and other causes. At present it is of particular interest to unravel why dopaminergic therapy is so efficient in the disease and why it leads to augmentation in some patients. Augmentation can be defined as a therapy induced paradoxical symptom severity increase caused by dopaminergic therapy. Augmentation occurs in about 60 % of patients preferentially on L-Dopa, but also on therapy with dopamine agonists. It is probably caused by a relative shift of the balance between excitatory dopaminergic D1-receptors and inhibitory D2-receptors at a spinal level. Iron deficiency is an initiating or strengthening factor. Therapy with L-Dopa or dopamine agonists should remain at distinctly lower doses than those commonly used in Parkinson's disease. Iron substitution and opiates are drugs of choice to minimize the risk of augmentation.

RLS - Restless-Legs-Syndrom - Pathophysiologie - Genetik - Dopamin - Opiate

RLS - restless legs syndrome - pathophysiology - genetics - dopamine - opiate

Literatur

• 1 Allen R P, Picchietti D, Hening W A. et al . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.  Sleep Med. 2003;  4 101-119
• 2 Vetrugno R, Contin M, Baruzzi A. et al . Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.  Mov Disord. 2006;  21 254-258
• 3 Ossipov M H, Lai J, King T. et al . Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.  Biopolymers. 2005;  80 319-324
• 4 Diener H C, Limmroth V. Medication-overuse headache: a worldwide problem.  Lancet Neurol. 2004;  3 475-483
• 5 García-Borreguero D, Allen R P, Kohnen R. et al, on behalf of the International Restless Legs Syndrome Study Group (IRLSSG) . Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a world association of sleep medicine - international restless legs syndrome study group consensus conference at the Max-Planck-Institute.  Sleep Med. 2007;  8 520-530
• 6 Trenkwalder C, Paulus W, Walters A S. The restless legs syndrome.  Lancet Neurol. 2005;  4 465-475
• 7 Wetter T C, Eisensehr I, Trenkwalder C. Functional neuroimaging studies in restless legs syndrome.  Sleep Med. 2004;  5 401-406
• 8 Cervenka S, Palhagen S E, Comley R A. et al . Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.  Brain. 2006;  129 2017-2028
• 9 Paulus W, Trenkwalder C. Less is more: Therapy-related augmentation of symptoms in Restless Legs Syndrome caused by dopaminergic overstimulation.  Lancet Neurology. 2006;  5 878-886
• 10 Allen R P, Barker P B, Wehrl F. et al . MRI measurement of brain iron in patients with restless legs syndrome.  Neurology. 2001;  56 263-265
• 11 Winkelmann J, Schormair P, Lichtner P. et al . Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions.  Nat Genet. 2007;  39 1000-1006, Epub 2007 Jul 18, PMID: 17637780 [PubMed - as supplied by publisher]
• 12 Stefansson H, Rye D B, Hicks A. et al . A genetic risk factor for periodic limb movements in sleep.  N Engl J Med. 2007, in press; 
• 13 Winkelmann J, Lichtner P, Schormair P. et al . Variants in the Neuronal Nitric Oxide Synthase (nNOS, NOS1) Gene are Associated with Restless Legs Syndrome.  Movement Disorders. 2007, in press; 
• 14 Trenkwalder C, Paulus W. Why do restless legs occur at rest? - Pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2).  Clin Neurophysiol. 2004;  115 1975-1988
• 15 Weerd A W de, Rijsman R M, Brinkley A. Activity patterns of leg muscles in periodic limb movement disorder.  J Neurol Neurosurg Psychiatry. 2004;  75 317-319
• 16 Bucher S F, Trenkwalder C, Oertel W H. Reflex studies and MRI in the restless legs syndrome.  Acta Neurol Scand. 1996;  94 145-150
• 17 Rijsman R M, Stam C J, Weerd A W de. Abnormal H-reflexes in periodic limb movement disorder; impact on understanding the pathophysiology of the disorder.  Clin Neurophysiol. 2005;  116 204-210
• 18 Bara-Jimenez W, Aksu M, Graham B. et al . Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex.  Neurology. 2000;  54 1609-1616
• 19 Paulus W, Schomburg E D. Dopamine and the spinal cord in Restless Legs Syndrome: Does spinal cord physiology reveal a basis of augmentation?.  Sleep Medicine Reviews. 2006;  10 185-196
• 20 Millan M J. Descending control of pain.  Prog Neurobiol. 2002;  66 355-474
• 21 Levant B, McCarson K E. D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function.  Neurosci Lett. 2001;  303 9-12
• 22 Zhao H, Zhu W, Pan T. et al . Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation.  J Neurosci Res. 2007;  85 1065-1076
• 23 Qu S, Le W, Zhang X. et al . Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome.  Journal of neuropathology and experimental neurology. 2007;  66 383-388
• 24 Baier P C, Ondo W G, Winkelmann J. Animal studies in restless legs syndrome.  Mov Disord. 2007, in press; 
• 25 Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).  Sleep Med. 2004;  5 385-391